Asuragen Initiates Launch of CE-Marked Molecular Diagnostic Products
Asuragen, Inc. has announced that the Signature(R) LTx v2.0 Leukemia Translocation Panel was released as a “Conformite Europeenne” or “European Conformity” CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The CE-marked Signature(R) LTx v2.0 is a qualitative in vitro diagnostic device for use in a clinical laboratory to identify specific fusion transcripts in total RNA from whole blood or bone marrow to aid in the clinical diagnosis of translocation positive leukemias. Clinical validation studies showed 100% diagnostic accuracy in comparison to standard cytogenetic methods. This represents the world’s first Luminex-based molecular oncology IVD product.
- Endologix Receives CE Mark Approval For Expanded Line Of Powerlink Products And PowerFit Aortic Extensions
- Abbott Gets FDA Clearance For Molecular Diagnostic Test For Detection Of Chlamydia And Gonorrhea Infections
- Cepheida receives approval for its bacterial diagnostic test
- Eisai, Sanko Junyaku launch pneumonia test kits
